{"organizations": [], "uuid": "7201cd9c6681a437ef77807cf7102c5fc21f64bd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-obseva-reports-positive-topline-re/brief-obseva-reports-positive-topline-results-from-implant2-phase-3-clinical-trial-of-nolasiban-in-ivf-idUSASB0C7DG", "country": "US", "domain_rank": 408, "title": "BRIEF-Obseva Reports Positive Topline Results From Implant2 Phase 3 Clinical Trial Of Nolasiban In IVF", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-26T14:40:00.000+02:00", "replies_count": 0, "uuid": "7201cd9c6681a437ef77807cf7102c5fc21f64bd"}, "author": "", "url": "https://www.reuters.com/article/brief-obseva-reports-positive-topline-re/brief-obseva-reports-positive-topline-results-from-implant2-phase-3-clinical-trial-of-nolasiban-in-ivf-idUSASB0C7DG", "ord_in_thread": 0, "title": "BRIEF-Obseva Reports Positive Topline Results From Implant2 Phase 3 Clinical Trial Of Nolasiban In IVF", "locations": [], "entities": {"persons": [{"name": "nolasiban", "sentiment": "none"}], "locations": [], "organizations": [{"name": "obseva sa", "sentiment": "none"}, {"name": "trial of nolasiban in ivf reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 26 (Reuters) - Obseva Sa:\n* OBSEVA SA REPORTS POSITIVE TOPLINE RESULTS FROM IMPLANT2 PHASE 3 CLINICAL TRIAL OF NOLASIBAN IN IVF\n* OBSEVA SA - ‍NOLASIBAN WAS WELL TOLERATED​\n* OBSEVA SA - FOLLOW-UP DATA FROM IMPLANT2 STUDY WILL INCLUDE LIVE BIRTH RATE, AND 28-DAY NEONATAL SAFETY, EXPECTED TO BE REPORTED IN Q4 OF 2018\n* OBSEVA SA - ‍IN ET D3 SUBGROUP, THERE WAS A STATISTICALLY NON-SIGNIFICANT 3.1% ABSOLUTE INCREASE IN FAVOR OF NOLASIBAN​\n* OBSEVA SA - SIX-MONTH INFANT FOLLOW-UP FROM IMPLANT2 STUDY IS EXPECTED TO BE AVAILABLE IN 2019\n* OBSEVA SA - ‍SAFETY PROFILE OF NOLASIBAN WAS ALSO SIMILAR TO PLACEBO​\n* OBSEVA SA - ‍NONE OF SERIOUS ADVERSE EVENTS WERE REPORTED TO BE RELATED TO TREATMENT​\n* OBSEVA SA - ‍IN ET D3 SUBGROUP, THERE WAS 14.0% RELATIVE INCREASE IN ONGOING PREGNANCY RATE AFTER ADMINISTRATION OF NOLASIBAN VERSUS PLACEBO​\n* OBSEVA SA - ‍IN ET D5 SUBGROUP, THERE WAS RELATIVE INCREASE IN ONGOING PREGNANCY RATE OF 32% AFTER ADMINISTRATION OF NOLASIBAN VERSUS PLACEBO​\n* OBSEVA SA - ‍IN ET D5 SUBGROUP, ABSOLUTE INCREASE WAS 11.2% IN FAVOR OF NOLASIBAN​ Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-02-26T14:40:00.000+02:00", "crawled": "2018-02-26T14:57:10.016+02:00", "highlightTitle": ""}